Stocks · Health care · Biological Products, (No Diagnostic Substances)

Replimune Group, Inc.

REPL Clue Score21
United States Fiscal year ends March CIK 0001737953 Results filed 28 Oct 2026

What the insiders did Net selling

Insider
Date
Role
Action
Shares
Price
Amount
Kapil Dhingra
2 Nov 2026
Director
Sold after exercise
21,500
$19.00
$408.50K
Emily Luisa Hill
17 Aug 2026
Chief Financial Officer
Sell
9,256
$14.28
$132.18K
Andrew Schwendenman
10 Aug 2026
Chief Accounting Officer
Sell
7,632
$12.97
$98.99K
Konstantinos Xynos
10 Aug 2026
Chief Medical Officer
Sell
11,447
$12.97
$148.47K
Emily Luisa Hill
10 Aug 2026
Chief Financial Officer
Sell
11,448
$12.97
$148.48K
Sushil Patel
10 Aug 2026
Chief Executive Officer
Sell
39,341
$12.97
$510.25K
Christopher Sarchi
1 Jun 2026
Chief Commercial Officer
Sold on a plan
12,000
$9.24
$110.88K
Emily Luisa Hill
18 May 2026
Chief Financial Officer
Sell
7,812
$5.08
$39.68K
Sushil Patel
18 May 2026
Chief Executive Officer
Sell
37,324
$5.08
$189.61K
Philip Astley-Sparke
18 May 2026
Director
Sell
17,657
$5.08
$89.70K
Christopher Sarchi
18 May 2026
Chief Commercial Officer
Sell
8,626
$5.08
$43.82K
Andrew Schwendenman
18 May 2026
Chief Accounting Officer
Sell
7,894
$5.08
$40.10K
Konstantinos Xynos
18 May 2026
Chief Medical Officer
Sell
14,023
$5.08
$71.24K
Christopher Sarchi
2 Apr 2026
Chief Commercial Officer
Sold on a plan
6,500
$8.01
$52.07K
Kapil Dhingra
9 Dec 2025
Director
Sold after exercise
3,169
$10.40
$32.96K
Sushil Patel
2 Dec 2025
Chief Executive Officer
Sold on a plan
10,000
$11.13
$111.30K
Konstantinos Xynos
17 Nov 2025
Chief Medical Officer
Sell
7,248
$9.10
$65.96K
Christopher Sarchi
17 Nov 2025
Chief Commercial Officer
Sell
5,208
$9.10
$47.39K

What was left out

Form 4 filings counted 40
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 2
Sales on a Rule 10b5-1 plan 3
Sales straight out of an exercise 2
Sales at will 13
Transactions with no price 0
Shares from compensation/vesting 974,245
History held since 25 Jul 2018